The efficacy of alogliptin and pioglitazone to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor

Not Applicable

• Conditions: Patients with type 2 diabetes

• Registration Number: JPRN-UMIN000015466
• Lead Sponsor: ational Hospital Organization National Kochi Hospital, Kochi, Japan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-10-20
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

severe diabetic ketosis diabetic coma or past history of pre-coma severe infection before or after operation or serious traumatic injury past history of hypersensitivity or allergic reaction to alogliptin and pioglitazone heart failure and past history of heart failure pregnancy or possibilty of pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes and %changes in gastrin and HbA1c after 6 months from baseline

Secondary Outcome Measures

Name	Time	Method
Changes and %changes in the following parameters during the observation period Body weight Fasting plasma glucose Office blood pressure Serum creatinine HDL TG LD